Previous 10 | Next 10 |
Flexion Therapeutics (FLXN) announces the appointment of Utpal Koppikar to the company's board of directors.Koppikar, Chief Financial Officer of Atara Biotherapeutics, will serve as the chair of Flexion’s audit committee.Prior to his tenure with Atara, Koppikar held...
BURLINGTON, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Utpal Koppikar, Chief Financial Officer of Atara Biotherapeutics, to its Board of Directors. Mr. Koppikar will serve as the chair of Flexion’s audit commit...
BURLINGTON, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 2021 Raymond James Human Health Innovation Conference. The...
Flexion Therapeutics (FLXN) announces the appointment of industry veteran William Andrews as the company's chief medical officer ((CMO)), effective July 1, 2021.Andrews has more than 20 years of experience in the biopharmaceutical industry, most recently serving as CMO at Akcea Ther...
BURLINGTON, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that William T. Andrews, M.D., F.A.C.P., will join the company as Chief Medical Officer (CMO), effective July 1, 2021. "Will brings an impressive combination of medical, clini...
BURLINGTON, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Virtual Confer...
The following slide deck was published by Flexion Therapeutics, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Flexion Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
BURLINGTON, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the RBC Capital Markets 2021 Virtual Global Healthcare Conferen...
Flexion Therapeutics, Inc. (FLXN) Q1 2021 Earnings Conference Call May 12, 2021 4:30 a.m. ET Company Participants Scott Young - VP of Corporate Communications & Investor Relations Michael Clayman - CEO Melissa Layman - Chief Commercial Officer David Arkowitz - CFO Fred Driscoll - Incoming...
Flexion Therapeutics (FLXN) reported a 22% jump in first-quarter sales, driven by strong demand for its knee pain drug ZILRETTA.The company said sales for ZILRETTA increased to $24.6M in the quarter, up from $20.1M in the prior-year period. The company's topline, however, missed analysts...
News, Short Squeeze, Breakout and More Instantly...
Flexion Therapeutics Inc. Company Name:
FLXN Stock Symbol:
NASDAQ Market:
Flexion Therapeutics Inc. Website:
-- Adds highly complementary ZILRETTA ® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- TAMPA, Fla. and BURLINGTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc...